Digital crowdsourcing: Unleashing its power in rheumatology (2020) Krusche M, Burmester GR, Knitza J Journal article, Review article PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis (2020) Zhang Y, Shen L, Zhu H, Dreissigacker K, Distler D, Zhou X, Györfi AH, et al. Journal article DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK (2020) Kreuter M, Bonella F, Riemekasten G, Mueller-Ladner U, Henes J, Siegert E, Guenther C, et al. Conference contribution CONTRIBUTION OF DEFECTIVE NON-APOPTOTIC FAS SIGNALING TO IMMUNE DYSREGULATION IN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) (2020) Staniek J, Kalina T, Andrieux G, Boerries M, Janowska I, Fuentes M, Bakardjieva M, et al. Conference contribution TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL (2020) Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES (2020) Mcgonagle D, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Kafka S, et al. Conference contribution NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL (2020) Volkmann E, Castellvi I, Johnson S, Matteson E, Distler J, Seibold J, Costabel U, et al. Conference contribution EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL (2020) Matteson E, Kelly C, Distler J, Hoffmann-Vold AM, Seibold J, Mittoo S, Distler O, et al. Conference contribution CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, et al. Conference contribution TARGET OUTCOMES IN PSA: SIMULTANEOUS ACHIEVEMENT OF ACR50-PASI100 AND BEYOND: INSIGHTS FROM SPIRIT-H2H AT WEEK 24 (2020) Smolen JS, Behrens F, Leage SL, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution